Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2022.Oct.03

Announcement of the expiration of AP Biosciences’ 2022 cash capital increase call period

2022.Sep.12

Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to TFDA

2022.Sep.10

Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP203, has been granted by US FDA

2022.Aug.31

Announcement on behalf of AP Biosciences that preemptive rights forfeited by all directors are over 50% and made available to specific persons

2022.Aug.31

Announcement on behalf of AP Biosciences’ call period of 2022 cash capital increase

2022.Aug.12

Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to US FDA

2022.Aug.11

Announcement of amendment of the Company's 2021 Annual Report

2022.Aug.08

Announcement on behalf of AP Biosciences that preemptive rights forfeited by directors are over 50% and made available to specific persons

2022.Aug.08

Announcement that the cumulative reduction of shareholding in major subsidiary, AP Biosciences, has reached more than 10%

2022.Aug.08

OBI forfeits subscription of AP Biosciences’ cash capital increase, distributes rights to its shareholders and sets target date

News

Latest news

Events

Latest events